{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T11:31:47Z","timestamp":1791891107182,"version":"4.3.4"},"reference-count":39,"publisher":"Elsevier BV","issue":"14","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003593","name":"CNPq","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"CAPES","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"name":"PRONEX","award":["2013\/50680-8"],"award-info":[{"award-number":["2013\/50680-8"]}]},{"DOI":"10.13039\/501100001807","name":"FAPESP","doi-asserted-by":"publisher","award":["2013\/07600-3"],"award-info":[{"award-number":["2013\/07600-3"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"FAPESP","doi-asserted-by":"publisher","award":["2014\/50249-8"],"award-info":[{"award-number":["2014\/50249-8"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.bmc.2018.06.033","type":"journal-article","created":{"date-parts":[[2018,6,25]],"date-time":"2018-06-25T12:54:53Z","timestamp":1529931293000},"page":"4065-4072","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Quinoxaline derivatives as potential antitrypanosomal and antileishmanial agents"],"prefix":"10.1016","volume":"26","author":[{"given":"Juliana","family":"Cogo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Cantizani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Cotillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0388-5409","authenticated-orcid":false,"given":"Diego Pereira","family":"Sangi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlene Gon\u00e7alves","family":"Corr\u00eaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T\u00e2nia","family":"Ueda-Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedito Prado Dias","family":"Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Julio","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celso Vataru","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2018.06.033_b0005","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1172\/JCI33945","article-title":"Kinetoplastids: related protozoan pathogens, different diseases","volume":"118","author":"Stuart","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bmc.2018.06.033_b0010","doi-asserted-by":"crossref","unstructured":"WHO. Working to Overcome the Global Impact of Neglected Tropical Diseases. Geneva: World Health Organization; 2010. doi: 10.1177\/1757913912449575.","DOI":"10.1177\/1757913912449575"},{"key":"10.1016\/j.bmc.2018.06.033_b0015","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.jacc.2013.05.046","article-title":"Chagas disease: an overview of clinical and epidemiological aspects","volume":"62","author":"Nunes","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.bmc.2018.06.033_b0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035671","article-title":"WHO leishmaniasis Control Team. Leishmaniasis worldwide and global estimates of its incidence","volume":"7","author":"Alvar","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bmc.2018.06.033_b0025","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/bmb\/lds031","article-title":"Management of trypanosomiasis and leishmaniasis","volume":"104","author":"Barrett","year":"2012","journal-title":"Br Med Bull"},{"key":"10.1016\/j.bmc.2018.06.033_b0030","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.actatropica.2018.02.010","article-title":"Recent progress in drug targets and inhibitors towards combating leishmaniasis","volume":"181","author":"Vijayakumar","year":"2018","journal-title":"Acta Trop"},{"key":"10.1016\/j.bmc.2018.06.033_b0035","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrmicro.2016.193","article-title":"Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need","volume":"15","author":"Field","year":"2017","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.bmc.2018.06.033_b0040","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.2174\/0929867322666150812144104","article-title":"Quinoxalines potential to target pathologies","volume":"22","author":"Trist\u00e1n-manzano","year":"2015","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.bmc.2018.06.033_b0045","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.ejmech.2017.11.064","article-title":"Quinoxaline: an insight into the recent pharmacological advances","volume":"143","author":"Tariq","year":"2018","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2018.06.033_b0050","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.ejmech.2014.08.034","article-title":"Present status of quinoxaline motifs: excellent pathfinders in therapeutic medicine","volume":"85","author":"Ajani","year":"2014","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2018.06.033_b0055","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.ejmech.2014.06.058","article-title":"Quinoxaline, its derivatives and applications: a state of the art review","volume":"97","author":"Pereira","year":"2015","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2018.06.033_b0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2016.00064","article-title":"Quinoxaline 1,4-di-N-oxides: biological activities and mechanisms of actions","volume":"7","author":"Cheng","year":"2016","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.bmc.2018.06.033_b0065","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1128\/AAC.02582-15","article-title":"In vitro and in vivo activities of 2,3-diarylsubstituted quinoxaline derivatives against Leishmania amazonensis","volume":"60","author":"Kaplum","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2018.06.033_b0070","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejmech.2014.11.018","article-title":"Synthesis and biological evaluation of novel 2,3-disubstituted quinoxaline derivatives as antileishmanial and antitrypanosomal agents","volume":"90","author":"Cogo","year":"2015","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2018.06.033_b0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0085706","article-title":"A quinoxaline derivative as a potent chemotherapeutic agent, alone or in combination with benznidazole, against Trypanosoma cruzi","volume":"9","author":"Rodrigues","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.bmc.2018.06.033_b0080","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.crci.2009.01.006","article-title":"Green chemistry approaches for the synthesis of quinoxaline derivatives: comparison of ethanol and water in the presence of the reusable catalyst cellulose sulfuric acid","volume":"12","author":"Shaabani","year":"2009","journal-title":"Comptes Rendus Chim"},{"key":"10.1016\/j.bmc.2018.06.033_b0085","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3998\/ark.5550190.0009.f24","article-title":"One-pot and efficient protocol for synthesis of quinoxaline derivatives","volume":"15","author":"Islami","year":"2008","journal-title":"Arkivoc"},{"key":"10.1016\/j.bmc.2018.06.033_b0090","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1590\/S0103-50532009000900016","article-title":"An efficient catalyst-free protocol for the synthesis of quinoxaline derivatives under ultrasound irradiation","volume":"20","author":"Guo","year":"2009","journal-title":"J Braz Chem Soc"},{"key":"10.1016\/j.bmc.2018.06.033_b0095","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/j.ejmech.2007.11.023","article-title":"Synthesis, antileukemic and antiplatelet activities of 2,3-diaryl-6,7-dihydro-5H-1,4-diazepines","volume":"43","author":"Ramajayam","year":"2008","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2018.06.033_b0100","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1128\/AAC.40.11.2592","article-title":"Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing beta-galactosidase","volume":"40","author":"Buckner","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2018.06.033_b0105","doi-asserted-by":"crossref","DOI":"10.1186\/1756-3305-2-54","article-title":"A luciferase based viability assay for ATP detection in 384-well format for high throughput whole cell screening of Trypanosoma brucei brucei bloodstream form strain 427","volume":"2","author":"Sykes","year":"2009","journal-title":"Parasit Vectors"},{"key":"10.1016\/j.bmc.2018.06.033_b0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pntd.0003493","article-title":"Automated high-content assay for compounds selectively toxic to Trypanosoma cruzi in a myoblastic cell line","volume":"9","author":"Alonso-Padilla","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.bmc.2018.06.033_b0115","doi-asserted-by":"crossref","first-page":"8771","DOI":"10.1038\/srep08771","article-title":"New compound sets identified from high throughput phenotypic screening against three kinetoplastid parasites: an open resource","volume":"5","author":"Pe\u00f1a","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmc.2018.06.033_b0120","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1128\/AAC.02398-12","article-title":"Comparison of a high-throughput high-content intracellular Leishmania donovani assay with an axenic amastigote assay","volume":"57","author":"de Rycker","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2018.06.033_b0125","first-page":"399","article-title":"Current scenario of drug development for leishmaniasis","volume":"123","author":"Croft","year":"2006","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.bmc.2018.06.033_b0130","doi-asserted-by":"crossref","first-page":"7719","DOI":"10.1021\/jm400362b","article-title":"Drug discovery for neglected diseases: molecular target-based and phenotypic approaches","volume":"56","author":"Gilbert","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2018.06.033_b0135","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.bmcl.2005.11.025","article-title":"Synthesis and antiprotozoal activity of some new synthetic substituted quinoxalines","volume":"16","author":"Hui","year":"2006","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2018.06.033_b0140","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.ejmech.2014.05.037","article-title":"Design, synthesis and biological evaluation of novel 4-alkapolyenylpyrrolo[1,2-a]quinoxalines as antileishmanial agents \u2013 Part III","volume":"81","author":"Ronga","year":"2014","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2018.06.033_b0145","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/0035-9203(87)90020-4","article-title":"Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease","volume":"81","author":"Filardi","year":"1987","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.bmc.2018.06.033_b0150","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/0035-9203(88)90208-8","article-title":"Comparative studies of drug susceptibility of five strains of Trypanosoma cruzi in vivo and in vitro","volume":"82","author":"Neal","year":"1988","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.bmc.2018.06.033_b0155","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ijantimicag.2012.08.002","article-title":"Evaluation of benznidazole treatment combined with nifurtimox, posaconazole or Am Bisome in mice infected with Trypanosoma cruzi strains","volume":"40","author":"Cencig","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.bmc.2018.06.033_b0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/molecules22020220","article-title":"Trypanocidal activity of quinoxaline 1,4 Di-N-oxide derivatives as trypanothione reductase inhibitors","volume":"22","author":"Chac\u00f3n-Vargas","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.bmc.2018.06.033_b0165","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1007\/s00436-014-3850-8","article-title":"Anti-Trypanosoma cruzi and anti-leishmanial activity by quinoxaline-7-carboxylate 1,4-di-N-oxide derivatives","volume":"113","author":"Villalobos-Rocha","year":"2014","journal-title":"Parasitol Res"},{"key":"10.1016\/j.bmc.2018.06.033_b0170","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ijantimicag.2017.04.016","article-title":"In vitro and in vivo assessment of newer quinoxaline\u2013oxadiazole hybrids as antimicrobial and antiprotozoal agents","volume":"50","author":"Patel","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.bmc.2018.06.033_b0175","doi-asserted-by":"crossref","first-page":"4498","DOI":"10.1016\/j.bmcl.2011.05.125","article-title":"New salicylamide and sulfonamide derivatives of quinoxaline 1,4-di-N-oxide with antileishmanial and antimalarial activities","volume":"21","author":"Barea","year":"2011","journal-title":"Bioorganic Med Chem Lett."},{"key":"10.1016\/j.bmc.2018.06.033_b0180","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1016\/j.bmcl.2017.02.049","article-title":"New hydrazine and hydrazide quinoxaline 1,4-di-N-oxide derivatives: in silico ADMET, antiplasmodial and antileishmanial activity","volume":"27","author":"Quiliano","year":"2017","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2018.06.033_b0185","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.bmc.2008.10.085","article-title":"Synthesis, antichagasic in vitro evaluation, cytotoxicity assays, molecular modeling and SAR\/QSAR studies of a 2-phenyl-3-(1-phenyl-1H-pyrazol-4-yl)-acrylic acid benzylidene-carbohydrazide series","volume":"17","author":"Vera-DiVaio","year":"2009","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2018.06.033_b0190","doi-asserted-by":"crossref","first-page":"5554","DOI":"10.1021\/jm300508n","article-title":"Novel 3-Nitro-1H-1,2,4-triazole-based Amides and Sulfonamides as Potential anti-Trypanosomal Agents","volume":"55","author":"Papadopoulou","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2018.06.033_b0195","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2174\/138945010790711996","article-title":"Halogen atoms in the modern medicinal chemistry: hints for the drug design","volume":"11","author":"Hernandes","year":"2010","journal-title":"Curr Drug Targets"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089618305856?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089618305856?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T00:56:07Z","timestamp":1760835367000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089618305856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":39,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S0968089618305856"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2018.06.033","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quinoxaline derivatives as potential antitrypanosomal and antileishmanial agents","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2018.06.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}